Journal of Clinical Oncology, Volume 44, Issue 5, Page 421-423, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 386-399, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 410-420, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 400-409, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 370-374, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 375-385, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 361-369, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 349-355, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 424-424, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 429-429, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 430-430, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 429-429, February 2026.

Journal of Clinical Oncology, Volume 44, Issue 5, Page 426-428, February 2026.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

New England Journal of Medicine, Volume 394, Issue 6, Page 529-539, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 563-575, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 576-587, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 614-616, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 622-623, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 619-620, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 624-624, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 597-599, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 589-595, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 588-588, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 526-527, February 5, 2026.

New England Journal of Medicine, Volume 394, Issue 6, Page 524-525, February 5, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

A 60-year-old man presented with a 15-day history of generalized weakness and right upper abdominal pain. Imaging studies revealed diffuse disruption of the hepatic architecture by hyperechoic nodules and areas of necrosis and hemorrhage.

In untreated HER2-positive metastatic breast cancer, trastuzumab deruxtecan plus pertuzumab extended progression-free survival to 40.7 months, vs. 26.9 months with standard first-line therapy, with a similar incidence of high-grade adverse events.

In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival.

A 29-year-old woman with active opioid, alcohol, benzodiazepine, tobacco, and cocaine use disorders and recent intravenous drug use presented with acute onset of chills and increased pain and drainage of chronic wounds in both legs.

A rare case of spontaneous heparin-induced thrombocytopenia occurred after hip arthroplasty despite no heparin exposure. Severe thromboses developed, but the patient recovered with bivalirudin and IVIG.

Medicare will achieve greater savings on the 15 drugs in its second round of price negotiations than it did in the first round. Despite new challenges, the effort should continue to pay growing dividends.

In acute central retinal artery occlusion treated within 4.5 hours after onset, intravenous tenecteplase did not result in greater recovery of vision at 30 days than aspirin and was associated with serious safety concerns.

In metastatic hormone-receptor–positive, HER2-positive breast cancer, maintenance palbociclib plus anti-HER2 and endocrine therapies extended progression-free survival but increased toxic effects such as neutropenia.

Among men with hemophilia B, sustained endogenous factor IX expression and low annualized bleeding rates over the course of 5 years were seen after an infusion of etranacogene dezaparvovec.

The U.S. government can combat chronic disease among Medicare patients by strengthening primary care, expanding access to preventive care, making care more affordable, and modernizing Medicare benefits.

A 55-year-old woman with invasive ductal carcinoma presented with a rash that had developed after a round of chemotherapy and had worsened and spread to her axillae, groin, and popliteal fossae after several additional rounds.

When a physician is notified that the blood she donated to a biobank revealed a nonfounder BRCA2 variant, the future she has long imagined for herself telescopes inward — yet she knows she is lucky.

The retina is a specialized patch of central nervous system tissue located at the back of the eye. When the principal source of oxygen and metabolic substrates to the retina — the central retinal artery — is occluded, rapid retinal cell death and loss of visual function ensue. This acute...

In patients with previously untreated, PD-L1–positive, advanced triple-negative breast cancer, sacituzumab govitecan plus pembrolizumab led to significantly longer progression-free survival than chemotherapy plus pembrolizumab.

In resected stage III or IV melanoma, nivolumab improved 9-year recurrence-free survival as compared with ipilimumab (44% vs. 37%), with no new late adverse events and fewer subsequent therapies needed.

The concept of adjuvant therapy for cancer was developed at a time when systemic cancer treatment was limited to cytotoxic chemotherapy that could only be administered intermittently but rarely resulted in a complete response. Skipper1 and others hypothesized that if treatment were started early in the disease course,...

Recent FDA actions related to leucovorin have caused confusion. There is still a lack of scientific evidence establishing that the drug is a safe and effective treatment for autism.

In 11 patients with multirefractory autoimmune hemolytic anemia, CD19 CAR T-cell therapy resulted in a complete response, drug-free remission lasting a median of 11.5 months, and expected toxic effects.

Congress is considering bills that would substantially expand Medicare coverage of certain products. The legislation could undermine CMS’s authority to implement evidence-based coverage policies.

Despite use of smokeless tobacco products by more than 360 million people globally and increasing incidence of oral cancers, research and policies on these products have lagged behind those for cigarettes.

Along with ongoing wars, territorial disputes, and instability in regions such as the Middle East, Europe, Latin America, and parts of Africa, there are continued changes and power shifts in the complex and turbulent geopolitical landscape. Unpredictable decisions with international consequences by the USA, under the leadership of President Donald J Trump, are of particular concern and are causing widespread political mayhem and impacting global stability, international cooperation, economic development, security, and humanitarian issues.

The therapeutic landscape of early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) has been irreversibly transformed by adjuvant EGFR tyrosine-kinase inhibitors.1 This paradigm shift began with the ADAURA trial, which established postoperative osimertinib as the first adjuvant targeted therapy to deliver durable survival benefit in molecularly defined NSCLC.2,3 Its effects extended beyond recurrence delay, providing clear evidence that early systemic intervention can improve cure rates and prevent metastatic relapse, especially in the brain.

Metastasis-directed therapy (MDT) delivered via stereotactic body radiotherapy has gained substantial attention over the past decade. Landmark trials such as STOMP1 and ORIOLE2 fundamentally shifted the management paradigm for metastatic prostate cancer. These pioneering studies showed improved progression-free survival in patients with up to three metastases compared with observation alone (HR 0·60, 95% CI 0·40–0·90 in STOMP; HR 0·30, 0·11–0·81 in ORIOLE). Subsequent phase 2 trials further expanded these findings: the EXTEND trials3,4 reported a progression-free survival benefit in patients with recurrent or de novo metastatic disease (five or fewer lesions) when MDT was added to either intermittent or continuous androgen deprivation therapy (ADT; HR 0·45, 0·30–0·69 in the combined analysis), and the RADIOSA5 study observed improved clinical progression-free survival with stereotactic body radiotherapy plus 6 months of ADT compared with stereotactic body radiotherapy alone (HR 0·43; 0·26–0·72).

Clear cell gynaecological tumours represent a paradigmatic example of the challenges of rare cancers, in which scarce clinical evidence contrasts with high unmet need, often affecting younger patients and raising concerns about equitable access to innovation. In The Lancet Oncology, Natalie Y L Ngoi and colleagues report the LARA (GCGS-OV4/APGOT-OV3) single-arm, multicentre, phase 2 trial of pembrolizumab plus lenvatinib in recurrent clear cell gynaecological cancer.1 Beyond its clinical findings, the study highlights the limitations of current evidentiary and regulatory frameworks for rare tumours.

In cancer trials, clinical investigators report and grade adverse events on behalf of their patients via the Common Terminology Criteria for Adverse Events (CTCAE) scale—including for highly subjective events such as fatigue, nausea, or sensory neuropathy. However, this approach has been found to be unreliable.

The recent media coverage of interim results from the PATHFINDER2 study of GRAIL's Galleri multicancer detection blood test exemplifies a troubling and recurring trend in science communication: the commercially driven, premature framing of non-peer-reviewed data as proof of a transformative breakthrough. Released via an embargoed press statement on Oct 17, 2025, and then presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress,1 the study's hand-picked performance metrics prompted a wave of enthusiastic, uncritical reporting across mainstream media outlets.

Oral cancer, ranked among the 16th most common cancers globally, represents a major public health burden.1 In some countries in south Asia, oral cancer is the most frequent cancer among men. A recent systematic analysis for the Global Burden of Disease study concluded that insufficient action in the past three decades has led to little change in population oral health, underscoring the necessity for renewed strategic focus.2

Over recent decades, advances in cancer treatment have yielded substantial improvements in patient outcomes, driving up survival, and even rendering some cancers curable. These advances have been achieved not only by remarkable scientific breakthroughs, but also by unprecedented financial investment in research and development, including the conduct of clinical trials of a size and complexity only feasible by the involvement of the commercial sector, predominantly, the pharmaceutical industry. However, therein lies a tension: the need to explore scientific truths versus a financial return on investment.

Alfredo Addeo

Salomon Manier and colleagues show that, in patients aged 65 years or older with newly diagnosed multiple myeloma selected for frailty, a regimen of lenalidomide plus daratumumab with dexamethasone confined to the first two cycles achieves markedly longer progression-free survival than continuous lenalidomide–dexamethasone, with an accompanying overall survival benefit and no clear excess of serious infections.1 For a population in whom steroids are often viewed as unavoidable, showing that a predominantly steroid-free backbone can be delivered for a median of almost 3 years is an important achievement.

We thank Yunfeng Fu and colleagues for their important comments on the IFM2017-03 trial1. We provide below the most accurate information available to address their remarks.

Samual X Stevens and colleagues advocate overall survival as the decisive trial endpoint.1 The authors overstate their case in saying that, “Oncology literature abounds with examples where reliance on putative surrogate endpoints has resulted in increased deaths.” They note that immunotherapy decreased myeloma overall survival, but the implication that surrogate endpoints suggested immunotherapy benefit was incorrect. Neither response rates nor progression-free survival indicated significant benefit.

We were surprised to read the letter from David J Stewart and colleagues in response to our Comment because they dismiss overall survival—the endpoint that patients have consistently reported as most meaningful1—as difficult and unreliable. We agree that measuring overall survival is difficult, but that cannot be an excuse to not measure it. We disagree that overall survival is unreliable. The literature is abound with plenty of examples where reliance on surrogates has caused harms and assert that ARIEL4 is one more example in that long list.

In 1971, Julian Tudor Hart wrote that “the availability of good medical care tends to vary inversely with the need of the population served”.1 Amid extraordinary progress in precision therapy, a quieter crisis has emerged viz the loss of the human face of cancer care. The Lancet Oncology Commission from Gary Rodin and colleagues on the human crisis in cancer2 exposes this paradox: that even as survival improves, the experience of illness often grows more fragmented, impersonal, and inequitable. Patients and their families shoulder catastrophic expenses without psychosocial support.

Stefano Kim and colleagues1 report promising activity from a combined neoadjuvant strategy using ezabenlimab (an anti-PD-1) with modified docetaxel, cisplatin, and fluorouracil (mDCF) followed by personalised intensity-modulated radiotherapy with involved-node chemoradiotherapy (INRT) in patients with stage 3 squamous cell anal carcinoma (SCAC). In this phase 2 trial, Kim and colleagues showed high rates of pathological (41 [84%] of 49 evaluable patients) and biological complete responses (36 [90%] of 40), concordant improvements in clinical complete response at 40 weeks (overall 77·8% [90% CI 66·5–86·7]), and encouraging early survival estimates (in a post-hoc analysis).

We thank Bhumesh Tyagi and colleagues for their comments. INTERACT-ION was designed to show the feasibility and preliminary efficacy of induction with modified docetaxel, cisplatin, and fluorouracil (mDCF) plus ezabenlimab then intensity-modulated radiotherapy with involved-node chemoradiotherapy (INRT) in patients with locally advanced squamous cell anal carcinoma (SCAC).1 We showed the value of this novel induction regimen, with 38 (75%) of 51 patients reaching a major response and becoming eligible for INRT with only four (11%) recurrences, suggesting that induction chemoimmunotherapy followed by INRT is a promising strategy for patients with locally advanced SCAC.

Cattley RC, De Roos AJ, Mandrioli D, et al. Carcinogenicity of atrazine, alachlor, and vinclozolin. Lancet Oncol 2026; 27: 11–12—In this News, the meta-odds ratio in the second sentence of the fifth paragraph should have been 1·99; 95% CI 1·13–3·53. This correction has been made to the online version as of Feb 2, 2026.

Sun J-M, Chao Y, Kim S-B, et al. First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial. Lancet Oncol 2026; 27: 90–102—This Article was published with the incorrect appendix file. The file has been corrected as of Feb 2, 2026.

In the phase 3 IidERA trial presented by Aditya Bardia (University of California Los Angeles, Los Angeles, CA, USA), adjuvant giredestrant, an oral selective oestrogen receptor degrader (SERD) showed significant improvement in invasive disease-free survival (iDFS) compared with standard-of-care endocrine therapy in patients with early-stage HR+ HER2– breast cancer. 4170 patients were randomly assigned (1:1) to receive either 30 mg of giredestrant or tamoxifen, letrozole, anastrozole, or exemestane.

Sperm from an otherwise healthy sperm donor—some of which harboured the TP53 gene mutation that causes a 90% lifetime cancer risk due to development of Li Fraumeni syndrome if passed to conceived children—has been used to father at least 197 children across Europe. Some of these children have already died from various cancers, and others have developed one or more cancers.

Global tobacco control measures have led to substantial decrease in the number of tobacco users—from 1·38 billion in 2000 to 1·20 billion in 2024, but there are concerns over possible undermining of these measures in some countries, due to untoward activities including illicit tobacco trade and interference of the tobacco industry in policy making.

Almost 70 million acres of US farmland might be contaminated with cancer-causing perfluoroalkyl and polyfluoroalkyl substances (PFASs), according to estimates from biosolids industry groups.

WHO is calling on governments to raise taxes on alcoholic beverages and sugary drinks after two new reports show both have become cheaper over the past few years. National tax policies should ensure these unhealthy products become less affordable over time, highlights WHO. However, the reports released on Jan 13, 2026, reveal that only 37 countries have achieved this trend for beer and only 34 for sugar-sweetened carbonated drinks. Allowing sugary drinks and alcohol to become more affordable will result in a rise in non-communicable diseases and injuries, warns WHO.

Under the Trump Administration, the US Environmental Protection Agency (EPA) plans to stop considering the lives and money saved by controlling air pollution caused by two pollutants—fine particulate matter (PM2·5) and ozone—while setting clean-air rules. According to the plan, instead of calculating the monetary value of saving human lives, EPA will focus only on the cost to the industry while setting rules for the pollution limits of PM2·5 and ozone.

Dirk De Ruysscher, *Pim J J Damen

Aumolertinib showed substantial clinical benefits as adjuvant therapy in Chinese patients with stage II–IIIB EGFR-mutated NSCLC. The manageable safety profile of aumolertinib supports its suitability in the adjuvant setting.

FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma. Thus, CE-T1MRI remains the preferred delineation method in this setting.

WOLVERINE showed a benefit with MDT for oligometastatic prostate cancer in progression-free survival, radiological progression-free survival, and castration resistance-free survival. Overall survival benefit was not significant and further research is needed.

Progression-free status at 24 months was a strong prognostic marker for overall survival at the patient level in HPV-positive oropharyngeal cancer and future trial-level analysis is now warranted. The adoption of this endpoint has the potential to accelerate therapeutic development by enabling earlier evaluation of treatment activity, thereby facilitating the timely introduction of novel therapies to this patient population before the availability of mature overall survival data.

Pembrolizumab plus lenvatinib showed promising anti-tumour activity and manageable safety in patients with recurrent CCGC, including in patients with disease progression following previous treatment with anti-angiogenic therapy. These findings support further evaluation of this combination in randomised controlled trials.

Correcting inequalities in implementation of minimally invasive surgical resection has the potential to reduce inequalities in colon cancer outcomes.

Cabozantinib with temozolomide showed a meaningful clinical benefit and could potentially be a viable treatment option for patients with unresectable or metastatic leiomyosarcoma. Treatment was tolerable and did not reveal any new safety signals.

Availability of PRO data to providers for CTCAE rating improves the consistency of provider-based symptomatic adverse event detection in patients with cancer. PRO data supports reliable assessment of treatment-related toxicity, highlighting the value of integrating PRO data into clinical evaluations within cancer trials.

Our model provides the basis for a clinically applicable deep-learning assistant to improve human efficiency and accuracy of CNS tumour diagnosis. The model will be made publicly available and could be implemented to assist human pathologists in future prospective studies.

The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse.

This Review underscores qualitative research as an indispensable facet of scientific inquiry to improve provision of safe, effective, and affordable care for patients with cancer worldwide. Representing a global working group of applied qualitative researchers, our multidisciplinary authorship team defines qualitative research, characterises its purpose and value, and describes specific ways in which qualitative inquiry is central to advancing cures, treatment, and quality of life in oncology. In this Review, we put forward an imperative for the use of qualitative methods to assess context, understand population needs, design interventions, optimise implementation, and investigate mechanisms of action underpinning changes in health outcomes.

Qualitative research is essential in addressing unresolved problems in oncology, yet high-yield strategies to bolster qualitative approaches in cancer research are scarce. To promote the unique strengths of qualitative research and increase uptake in the field of oncology, qualitative methods should show quality and credibility on par with quantitative methods. This Review presents recommendations for applied qualitative cancer research generated by multidisciplinary experts who were invited to attend the Symposium on Applied Qualitative Research, held on Nov 11–12, 2024, based on their contributions to the field.

As cancer survivors live longer, technologies improve, and reirradiation (reRT) becomes more common, standardised methods for the assessment and reporting of cumulative radiation doses are needed to allow treatment optimisation and integration with other medical specialties managing these complex patients. This consensus statement, developed by an international collaboration of radiation oncologists, physicists, and other experts in the Reirradiation Collaborative Group, proposes a framework for consistent evaluation, documentation, reporting, and clinical decision making in reRT.

Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of life and overall survival. Clinical trials have used inconsistent definitions, criteria, and endpoints, limiting comparability. We conducted a Delphi consensus process following a systematic review of prospective MSCC trials from Jan 1, 2003, to Feb 26, 2024. From June 25, 2024, to Jan 11, 2025, experts from 20 countries participated in two survey rounds, 74 in round 1 and 71 in round 2.

The UK National Health Service (NHS) will meet all three core cancer standards by 2029, according to a new National Cancer Plan for England, published on Feb 4, 2026. This is despite national treatment targets having not been hit for more than a decade.

On Jan 27, 2026, India and the EU announced the conclusion of a comprehensive free trade agreement (FTA) as part of the 16th EU–India Summit, held in New Delhi, India. The new agreement creates a free trade zone affecting more than 2 billion people by eliminating or reducing tariffs on chemical inputs, medical devices, and pharmaceuticals, including cancer drugs.

This 10-year follow-up confirms the non-inferiority of the ultra-hypofractionated radiotherapy regimen compared with the conventionally fractionated, with similar toxicity profiles. The findings support the seven-fraction schedule as a safe, effective, and practical standard-of-care option for patients with intermediate-risk prostate cancer.

Lithuania has now joined a growing list of more than 100 countries worldwide that have introduced a tax on sugar-sweetened beverages (SSBs). The tax, introduced from Jan 1, 2026, means the Baltic nation is one of many countries using fiscal policies to help encourage healthier diets across its population. Lithuania will also be taxing artificially sweetened beverages.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) began as therapies for type 2 diabetes but have become a breakthrough therapy for obesity, redefining its treatment and broader metabolic landscape. They have lit up medicine, popular culture, and global markets as new benefits and controversies unfold, with no field of medicine immune. By mimicking GLP-1 physiology, these drugs have come a long way, from the US Food and Drug Administration approval to treat type 2 diabetes in 2005 to approval to treat obesity in 2014, peaking with the 2021 subcutaneous weekly semaglutide regimen that delivered unprecedented weight loss.

Chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibodies (BsAb) are T-cell redirecting therapies that have revolutionised the treatment landscape for relapsed or refractory large B-cell lymphoma. However, the optimal sequencing of these treatments remains elusive.1

Heitmann JS, Maringer Y, Jung S, et al. Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study. Lancet Haematology 2026; 13: e74–85—In this Article, Ariane Metzger's surname and Melissa Zwick's degree qualification were amended. Mark Polster's affiliations should have been “Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany”, “Department of Peptide-based Immunotherapy, University and University Hospital of Tübingen, Tübingen, Germany”, and “Department of Computer Science, University of Tübingen, Tübingen, Germany”.

Hisham Abdel-Azim (Loma Linda, CA, USA) and colleagues presented results from the multicentre phase 2 EndRAD trial (NCT03509961) examining myeloablative non-total-body-irradiation conditioning regimens for allogeneic HSCT in patients (aged 1 year to <31 years) with B-ALL at lower relapse risk. 51 patients underwent HSCT and, at a median follow-up of 2·3 years (range 0·2–6·0), the primary endpoint of 2-year event-free survival (EFS) was 76·3% (95% CI 61·1–86·1). Transplant-related mortality in the first 100 days after HSCT was 2%.

In his father's small grocery store in Mexico City, Jorge Cortes learnt the meaning of hard work. Learning English from an early age and with parents who placed high importance on studying, Cortes, now director of the Georgia Cancer Center in Augusta, GA, USA, was talked out of becoming a dentist by his grandfather. “He was very influential in my life, and he said to me ‘You're too smart. Why don't you go for the whole thing, not just the mouth,’” Cortes recalls.

Chlorosis (c.1899) by Sebastià Junyent captures the viewer's attention with its muted tone (figure). We see a young woman slumped in her chair, her pale skin set against an interior of olives and greys. Supporting the woman is a second character wearing a blue dress with rosy red cheeks, providing a picture of healthy complexion in comparison. The contrast is deliberate: pale beside rosy, slumped besides upright. This chromatic choice would be recognised by 19th century viewers as chlorosis—also known as the green sickness—which comprised fatigue, pallor, and amenorrhoea in adolescent girls and young women.

Four interventions used to prevent donation-related vasovagal reactions showed no clear benefits compared with standard practices in England, suggesting potential policy implications for blood services worldwide to streamline donation practices and save resources.

Our findings indicate that iTAC-XS15-CLL01 could be a potent immunotherapeutic agent in patients with chronic lymphocytic leukaemia and should be further evaluated in phase 2 trials.

Based on current evidence, our meta-analysis suggests that BsAb therapy before CAR-T could improve future CAR-T effectiveness for large B-cell lymphoma, although our conclusions are limited by small sample sizes. Nonetheless, our findings have important implications for the design of randomised controlled trials to identify the optimal treatment sequence of CAR-T and BsAb.

These findings support the beneficial effect of resminostat maintenance therapy in patients with advanced CTCL. The overall safety profile of resminostat was acceptable, with gastrointestinal side-effects occurring most frequently. Anti-emetic prophylaxis should be considered in the future to manage side-effects and to improve tolerability and adherence to maintenance therapy.

Haematological disorders constitute a public health crisis in more than 160 countries worldwide. Despite millions afflicted, people with haematological diagnoses remain underserved and understudied. This Review, one of four companion Reviews on qualitative research published in The Lancet Oncology, The Lancet Haematology, and eClinicalMedicine, reports findings from a symposium of international multidisciplinary experts in applied qualitative research, highlighting the purpose and added value of qualitative research for improving health outcomes for people with haematological disorders and their communities.

In acute myeloid leukemia clinical trials, most patients receiving triplet therapy with venetoclax-azacitidine plus an agent targeted to the leukemia’s driver mutation achieve remission, but outcomes are variable and mechanisms of resistance have typically been inferred by analysis of specimens at relapse. Turkalj and colleagues used high-sensitivity single-cell genotyping and RNA sequencing to sequentially characterize the clonal evolution and transcriptional changes occurring in defined bone marrow populations in IDH1-mutant myeloid malignancy treated with ivosidenib-venetoclax with or without azacitidine and found that rapid emergence of resistant clones with distinct expression characteristics occurs within 1 to 3 months of treatment initiation, foreshadowing overt clinical relapse years later. The data in this Plenary Paper provide new insights as to when and how to intervene to circumvent resistance.

Prevention of acute and chronic graft-versus-host disease (GVHD) remains a priority area for improvement in allogeneic hematopoietic stem cell transplantation practice. Curtis and Hill provide a Blood Spotlight review of recent practice-changing advances that incorporate posttransplant cyclophosphamide into routine GVHD prophylaxis for matched sibling and unrelated-donor transplants. They also look to the future and outline the key questions that future trials must address to further reduce GVHD-related morbidity and mortality while also reducing the risk of toxicity and relapse.

To maximize the relevance of therapeutic clinical trials to everyday patients, we need to reduce unnecessary eligibility barriers, and the Food and Drug Administration (FDA) has recently provided guidance in this regard. Hantel et al operationalize this guidance into “safety-based” criteria, enabling comparison between these and actual eligibility criteria from 190 phase 2/3 acute myeloid leukemia (AML) trials. For a real-world cohort of more than 2200 patients with AML, they report that modernized, safety-based criteria could nearly double trial eligibility, with especially pronounced gains among historically underserved groups. The onus now is on clinical trialists and product sponsors to adopt these more representative eligibility criteria.

Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase that coordinates lysosomal acidification, endosomal trafficking, and autophagy and is a potential point of vulnerability in multiple myeloma (MM) cells given that high immunoglobulin production imposes major protein-misfolding stresses. Bonolo de Campos and colleagues report the development and characterization of selective small-molecule inhibitors targeting PIKfyve and, using preclinical models, reveal downstream consequences of its inhibition, which include cytotoxicity, upregulation of class I major histocompatibility complex expression, and dysregulation of cholesterol metabolism. In vitro activity extends beyond myeloma cells to other tumors, and these inhibitors now require optimization for in vivo studies to test their potential as therapeutics.

TP53 loss decouples lethal intracellular stress from the triggering of apoptosis, and this contributes to the therapeutic resistance commonly seen in TP53-mutant acute myeloid leukemia (AML). Semba et al employed genome-wide CRISPR/Cas9 dropout screens in TP53 wild-type and knockout AML models, combined with transcriptomic and proteomic analyses, to demonstrate that TP53 mutations rewire the histone regulatory network by upregulating the nuclear transport receptor XPO7. This enables AML cells to cope with replication stress, maintain genome integrity, and sustain an aggressive phenotype and may prove to be a tractable vulnerability.

For all we understand about the fetal-to-adult switch in usage of β-globin cluster genes, its intricate regulation remains incompletely understood. Bagchi et al reveal, for the first time, that specific chromatin-remodeling machines such as the Brahma-associated factor (BAF) complexes play different roles at the γ-, δ-, and β-globin genes in both erythroid cell lines and primary human erythroid progenitors. Their findings may point to new pathways to reactivate fetal hemoglobin (α₂γ₂) expression.

Exposure to cell membrane–associated tissue factor (TF), also known as coagulation factor III and the product of the F3 gene, is the triggering event that initiates the clotting cascade in normal hemostasis and a wide variety of thrombotic disorders. Utilizing publicly available genomic sequencing data, site-directed mutagenesis, and analyses of electronic medical record data linked to a large exome-sequenced biobank, Ansari et al report the first human population study to identify rare missense mutations in F3 that cause in vitro defects in tissue factor clotting activity. They identified 2 general classes of functionally defective variants, setting the scene for future investigation of the relevance of these variants to patients with unexplained bleeding disorders.

One in eight patients who undergo prostatectomy experience PPP. These patients constitute a unique, high‐risk population distinct from patients who have NED and BCR. Clinical trials addressing optimal treatment and intensity for these at‐risk patients are critically warranted.

Regional nodal irradiation (RNI) increases breast cancer related lymphedema (BCRL) following axillary lymph node dissection (ALND) despite immediate lymphatic reconstruction (ILR). This study examines the relationship between radiation (RT) dose to the ILR anastomosis and BCRL.

: The association between late toxicity and biochemical recurrence (BCR) following prostate radiotherapy is unclear. We set out to characterize the relationship between late gastrointestinal (GI) and genitourinary (GU) toxicity and BCR among patients receiving conventionally fractionated (CF) or moderately hypofractionated (MHF) prostate radiotherapy.

Normal tissue doses associated with contemporary mediastinal RT produce lower predicted SMN risks than were observed in cohorts treated with historical RT approaches, with substantial variation among individuals. On average, proton therapy is associated with a lower predicted risk. These findings have implications for the selection of therapies, counseling of patients, planning of RT, and recommendations for SMN screening.

Recurrent WHO grade 4 gliomas have poor outcomes and limited salvage options. Re-irradiation (re-RT) can provide local control in selected patients but is constrained by cumulative dose and toxicity. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) delivers re-RT as high-dose “pulses” spaced weeks apart, creating opportunities for interim MRI assessment and adaptive replanning on an MRI-linear accelerator (MR-Linac).

While technical advances have allowed for reduced radiation doses to the lungs and heart when treating esophageal cancer (EC), doses to these organs cannot yet be eliminated completely. We conducted a post hoc analysis of CALGB 80803 (Alliance) to evaluate whether the radiation doses delivered to the heart and lungs in a prospective study with robust quality assurance were associated with overall survival (OS), and we assessed the impact of intensity modulated radiation therapy (IMRT) on adherence with protocol-specified dose constraints.

In re-irradiation, tumor control must be balanced against a high risk of adverse effects. We evaluated the feasibility of a time-dependent recovery model to improve toxicity prediction.

In oncology, evolution occurs, but on a much faster time scale than in nature. Cancer treatment evolves, often under the selective pressures of clinical trials. Treatments that lack demonstrated benefit become “unfit” and disappear, while those with clinical value survive and shape the next generation of care. Over the past couple of decades, several once-routine radiotherapy indications have vanished, like adjuvant para-aortic radiation for testicular cancer, elective nodal irradiation in non-small cell lung cancer, extended fields for lymphoma, and others.

Biology-guided radiotherapy (BgRT), a novel treatment approach, integrates real-time PET imaging with external beam delivery to enable tumor-targeted dose modulation. Lung tumors, given their high FDG uptake and low background activity, are considered ideal candidates for BgRT. This study presents the first clinical experience of BgRT in lung cancer, evaluating treatment workflow, plan quality, PET signal characteristics, and delivery timing.

Radiotherapy treatment planning hinges on a critical factor: the prescribed dose. Surprisingly, there is no consistent, standardised global approach to evaluating the dosimetry of this prescription across different centres treating head and neck cancer (HNC). This study aimed to quantify global dose variations for identical prescriptions across international centres treating oropharyngeal cancer, to establish the foundation for future outcome-based studies and improve consistency of interpretation worldwide.

The Spinal Instability in Neoplasia Score (SINS) is the gold standard to determine if the metastatically involved spine is stable, potentially unstable, or frankly unstable. In potentially unstable spines, clarity is needed about the risk of post-stereotactic body radiation therapy (SBRT) vertebral compression fracture (VCF) and which patients may benefit from early stabilization. We aimed to identify predictors of VCF following spine SBRT in patients with potentially unstable SINS spinal metastases..

During the past decade, a deepening awareness of the importance of well-being among healthcare professionals has coalesced.1 Yet this awakening has not occurred in a vacuum. Across the United States and the world, people are navigating unprecedented stressors: rapid technological and societal change, widened political polarization, armed conflicts, natural disasters worsened by climate change, and economic as well as social uncertainty. Against this backdrop, mental health difficulties have become a major challenge in multiple regions and population groups, and healthcare professionals are not immune.

Deformable dose mapping (DDM) and accumulation (DDA) are essential tools in lung cancer stereotactic body radiation therapy (SBRT). Here we provide a critical review of deformable image registration (DIR)–based dose mapping and accumulation techniques in stereotactic body radiation therapy (SBRT) for lung cancers, with emphasis on methodological principles, clinical applications, limitations, and guidance for practice. A broad appraisal of the literature was conducted, emphasizing deformable image registration (DIR) algorithms and related dose mapping strategies, including direct dose mapping (DDM), voxel warping, and energy/mass-congruent mapping (EMCM).

The use of SABR for oligometastatic cancer is expanding, but prospective long-term survival data are limited. This study reports long-term secondary outcomes of overall survival (OS), progression-free survival (PFS), local control, and prognostic factors from the population-based phase 2 SABR-5 trial.

Stereotactic ablative body radiotherapy (SABR) is an emerging indication for localized renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices, as accurate target delineation is essential to ensure optimal outcomes. Our objective was to develop consensus guidelines for target volume contouring for RCC SABR.

Immuno-radiobiology is an interdisciplinary field exploring the interactions between ionizing radiation therapy, the tumor-immune microenvironment, and the immune system. The immune response to radiation is an important contributor to the efficacy of radiotherapy and has the potential to influence susceptibility to immunotherapies. Preclinical and some clinical evidence suggest combinations of radiotherapy with immunotherapies improve tumor response, but a greater understanding of their interacting mechanisms is needed to optimize these combinations.

Pelvic radiation therapy is central to the curative treatment of a range of malignancies, including rectal, anal, gynecologic, and pediatric pelvic tumors, but it inevitably leads to irreversible damage to reproductive organs.1 The ovaries are exquisitely radiosensitive, and doses as low as 2 Gy can impair ovarian reserve, whereas cumulative doses above 6 to 10 Gy usually result in permanent ovarian insufficiency.2 The uterus is also profoundly affected, because radiation therapy induces endometrial atrophy, myometrial fibrosis, and vascular compromise, resulting in amenorrhea, uterine shrinkage, and complete loss of reproductive capacity.

When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...

The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...

Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%.

An artificial intelligence (AI)-based risk prediction model, ONCO-ACS, showed possible favorable clinical utility as a practical tool for predicting cardiovascular death, myocardial infarction, and ischemic stroke events in patients with cancer and acute coronary syndrome, according to findings...

As reported in the Journal of Clinical Oncology by Iveson et al, final results of the UK-based noninferiority phase III SCOT trial have shown noninferiority of 3 vs 6 months of adjuvant oxaliplatin plus fluoropyrimidine chemotherapy in overall survival among patients with colorectal cancer....

As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...

Sako et al conducted a prognostic study to evaluate whether a fully automated deep-learning radiomic biomarker based on serial CT scans could improve prediction of overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. Their findings,...

In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...

A randomized, controlled clinical trial for artificial intelligence (AI)–supported mammography readings, called the MASAI trial, demonstrated that AI reads of mammogram scans led to fewer interval breast cancer diagnoses than with standard double reads by radiologists, according to findings...

A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy.

Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ancestry, according to a new review study published by Ndahayo et al in Cancer and Metastasis Reviews.

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in neoadjuvant treatments, such as chemotherapy, immunotherapy, and hormone therapy, often allowing for less invasive surgery and helping clinicians assess how a...

The Cancer Research Institute (CRI) in collaboration with 10x Genomics, Stanford University School of Medicine, the University of Pennsylvania Perelman School of Medicine, and Memorial Sloan Kettering Cancer Center, has launched an open foundational database for cancer immunotherapy research. The

Tuesday, January 27, 2026 9:00 AM

---

Adjuvant Durvalumab in Resected Early-Stage NSCLC

In a phase III trial (Canadian Cancer Trials Group BR.31) reported in the Journal of Clinical Oncology, Goss et al found that adjuvant durvalumab did not improve disease-free survival vs placebo in patients with completely resected early-stage non–small cell lung cancer (NSCLC).

---

Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25%

A team of researchers and physicians found that utilizing ultrasound-guided diffuse optical tomography (DOT) technology may reduce unnecessary breast biopsy rates by nearly 25%. Using this new method first—rather than starting with a biopsy—may help to determine if additional diagnoses are needed...

Friday, January 30, 2026 11:56 AM

---

AACR Announces Fellows of the AACR Academy Class of 2026

The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy.

Friday, January 30, 2026 12:13 PM

---

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

In a cohort study analysis reported in the Journal of Clinical Oncology, Valenza et al found that extended endocrine therapy after 5 years of adjuvant luteinizing hormone–releasing hormone agonist (LHRHa) treatment was associated with benefit among premenopausal women with node-positive, hormone...

---

Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus, Esophageal Cancer

The Spray Cryotherapy Esophageal Consortium has developed a set of expert and evidence-based consensus recommendations guiding the use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. The recommendations, decided upon through a modified Delphi process, were...

Friday, January 30, 2026 9:00 AM

---

Machine Learning–Enhanced Prognostic Scoring Predicts Survival and Classifies Risk From Spinal Metastases

A prognostic scoring system for predicting 1-year survival in patients with advanced cancer and spinal metastases was enhanced with machine learning for greater accuracy, according to the results of a Japanese multicenter study published in Spine. 

Friday, January 30, 2026 9:00 AM

---

Can Color Vision Deficiency Impact Survival in Bladder or Colorectal Cancer?

Color vision deficiency is an inherited condition affecting 1 in 12 males  (8%) and 1 in 200 females (0.5%), most often impairing the ability to distinguish the color red. A recent study published in Nature Health examined the possible impact of color vision deficiency on survival outcomes among...

---

Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers

In a comprehensive molecular characterization of the most common type of head and neck cancer, researchers from the United States and Poland have clarified the contribution of key cancer-associated genes, proteins, and signaling pathways in these cancers, while proposing possible new treatment...

Monday, January 11, 2021 12:48 PM

---

Emergency Department Use and Unplanned Hospitalization Among Patients With Head and Neck Cancer: Association With Reported Symptom Burden

In a Canadian population-based study reported in the Journal of Clinical Oncology, Noel et al found that patient-reported symptom burden was significantly associated with the likelihood of emergency department use and unplanned hospitalization among patients with head and neck cancer.

---

Reduced-Dose Intensity-Modulated Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma

In the phase II NRG Oncology HN002 trial reported in the Journal of Clinical Oncology, Sue S. Yom, MD, PhD, and colleagues found that a reduced-dose intensity-modulated radiation therapy (IMRT) regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma satisfied...

---

Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma

In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that endoscopic nasopharyngectomy was associated with improved overall survival vs intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent nasopharyngeal carcinoma who had received prior...

---

FDA Pipeline: Designations in Ovarian, Head/Neck, and Thyroid Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a novel immunotherapy for the treatment of ovarian cancer as well as Breakthrough Therapy designation to treatments for HRAS-mutant head and neck squamous cell carcinoma and previously treated thyroid cancer....

Friday, March 5, 2021 1:08 PM

---

FDA Pipeline: Novel Treatments in Lymphoma, Nasopharyngeal Cancer, Solid Tumors, and More

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for several kinds of lymphoma, as well as nasopharyngeal cancer; a Breakthrough Therapy designation for a treatment for patients with NTRK-positive advanced solid tumors; and Fast Track designation for...

Tuesday, November 2, 2021 1:58 PM

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Platelets can promote cancer progression through either direct and indirect mechanisms, and they can also suppress tumour progression in certain contexts. The authors of this Review discuss how insights on these properties have been leveraged to develop cancer therapies in which platelets are engineered to act as targeted delivery vehicles or as active effector cells, outlining opportunities and challenges for clinical translation.

Novel immunotherapy combinations are now available for second or later-line therapy for follicular lymphoma. The addition of tafasitamab, an anti-CD19 antibody, or epcoritamab, a CD20 × CD3 bispecific antibody, to lenalidomide–rituximab (R2) has demonstrated promising efficacy. Herein, I compare recent phase III trials testing each combination and discuss their practical implications.

Premenopausal women aged <40 years diagnosed with oestrogen receptor-positive early-stage breast cancer have disproportionately poorer outcomes relative to older women. The authors of this Review propose a biology-driven approach to challenge the conventional sequencing of chemotherapy and endocrine therapy in this population.

Anbenitamab is a new second-line option in G/GEJ adenocarcinoma

This Review outlines the fundamental role of chimeric antigen receptor (CAR) T cell therapy for children, adolescents and young adults (CAYAs) with relapsed and/or refractory B cell acute lymphoblastic leukaemia, emphasizing the crucial need to further exploit CAR T cells and other immunotherapies to improve survival with broadened access across disease states. Opportunities and challenges for expanding CAR T cell therapy to other haematological and non-haematological malignancies in CAYAs are also discussed.

Increased understanding of the biology of smouldering multiple myeloma (SMM) is being leveraged to improve the management of this clinically heterogeneous precursor of MM. This Review describes the current diagnostic work-up, risk stratification and management of SMM, highlighting early intervention approaches for high-risk SMM that might provide the best opportunity to convert MM into a curative disease and discussing persistent challenges in this field.

Author Correction: Advances in the management of localized bladder cancers

Despite well-established roles of microRNAs (miRNAs) as tumour suppressors or oncogenes, miRNA-based diagnostics, prognostic tools and treatments have yet to be incorporated into routine oncology practice. In this Review, the authors discuss innovative approaches to address challenges in the clinical translation of miRNA-based diagnostics and treatments by integrating fundamental miRNA biology, multiomics and artificial intelligence-driven analyses.

Annals of Internal Medicine, Volume 179, Issue 1, Page 1-11, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 12-22, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 23-31, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 32-41, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 42-50, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 51-66, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 67-80, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 81-94, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 95-106, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 110-117, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 107-109, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 118-124, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 125-126, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 127-128, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 129-130, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 131, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 132-133, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 134-135, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 136-137, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 138-139, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 140-141, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 142, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 143, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 144-145, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 147-149, January 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 1, Page 149-152, January 2026. <br/>

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, “Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets said Tuesday.

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients with type 2 diabetes.

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.

The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.

Insmed pointed to a strong placebo response as the reason for the trial’s failure.

In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.

Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.

Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.

The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts.

Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.

With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.

The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with immuno-oncology heavyweight Keytruda.

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.

Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, “Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets said Tuesday.

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.

AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.

With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”

In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.

The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.

On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).

On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.

On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.

On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy

On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.

On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.

On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.

On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024). 

On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.

On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.

On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).

On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.

On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.

On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.

On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.

Cell. 2026 Jan 29:S0092-8674(25)01498-9. doi: 10.1016/j.cell.2025.12.049.
Hanahan D

Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10059-1.
Ren J, Zhang W, Dahmani L, Gordon EM, Li S, Zhou Y, Long Y, Huang J, Zhu Y, Guo N, Jiang C, Zhang F, Bai Y, Wei W, Wu Y, Bush A, Vissani M, Wei L, Oehrn CR, Morrison MA, Zhu Y, Zhang C, Hu Q, Yin Y, Cui W, Fu X, Zhang P, Wang W, Ji GJ, He J, Wang K, Fan D, Wang Z, Kimberley T, Little S, Starr PA, Richardson RM, Li L, Wang M, Wang D, Dosenbach NUF, Liu H

Nat Med. 2026 Feb 2. doi: 10.1038/s41591-025-04181-w.
Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Lévi F, Yang N, Zhang Y

Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10084-0.
Tan JX, Lv B, Li J, Li T, Du F, Chen X, Zhang X, Bai XC, Chen ZJ

Nat Med. 2026 Feb 3. doi: 10.1038/s41591-026-04219-7.
Fink H, Langselius O, Vignat J, Rumgay H, Rehm J, Martinez RX, Santero M, Lopez-Perez L, Inoue M, Zeng H, Shield K, Morgan E, Ilbawi A, Soerjomataram I

Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10028-8.
Wei HK, Yu CD, Hu B, Zeng X, Ichise H, Li L, Wang Y, Wang RL, Germain RN, Chang RB, Jin C

Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10036-8.
Li X, Lebeaupin C, Kadianaki A, Druelle-Cedano C, Vesper N, Rennert C, Huguet-Pradell J, Gomez Ramos B, Fan C, Piecyk RS, Zizmare L, Ramadori P, Li L, Frick L, Qiu M, Zhang C, Martins Nascentes Melo L, Ranvir VP, Shen P, Hanselmann J, Kosla J, Fernández-Vaquero M, Vucur M, Baskaran P, Bao X, Coleman OI, Tang Y, Cetin M, Chen Z, Jang I, Del Prete S, Rahbari M, Zhang P, Pham TV, Hou Y, Sun A, Gu L, Kim LC, Rothermel U, Heide D, Ali A, Gallage S, Talvard-Balland N, Piqué-Gili M, Gris-Oliver A, Bevilacqua A, Schlicker L, Duffey A, Unger K, Szydlowska M, Hetzer J, Odom DT, Machauer T, Bucci D, Sant P, Lee JH, Rösler J, Meckelmann SW, Schreck J, Murray S, Simon MC, Nahnsen S, Schulze A, Ho PC, Jugold M, Breuhahn K, Mallm JP, Schirmacher P, Roth S, Rahbari N, Tschaharganeh DF, Roessler S, Goeppert B, Bengsch B, Andrieux G, Boerries M, Malek NP, Prinz M, Weber A, Zeiser R, Tamayo P, Bronsert P, Kurowski K, Thimme R, Yuan D, Carretero R, Luedde T, Pinyol R, Hartmann FJ, Karin M, Tasdogan A, Trautwein C, Mall M, Hofmann M, Llovet JM, Haller D, Kaufman RJ, Heikenwälder M

Lancet Reg Health Eur. 2026 Jan 29;62:101566. doi: 10.1016/j.lanepe.2025.101566. eCollection 2026 Mar.
NIHR Global Health Research Unit on Global Surgery

Nature. 2026 Feb;650(8100):49-59. doi: 10.1038/s41586-025-10018-w. Epub 2026 Feb 4.
Zetterberg H, Bendlin BB

Nature. 2026 Feb 4. doi: 10.1038/s41586-025-09989-7.
Chung HK, Liu C, Battu A, Jambor AN, Pratt BM, Xie F, Riesenberg BP, Casillas E, Sun M, Landoni E, Li Y, Ye Q, Joo D, Green J, Syed Z, Brown NJ, Smith M, Ma S, Tan S, Chick B, Tripple V, Wang ZA, Wang J, Mcdonald B, He P, Yang Q, Chen T, Varanasi SK, LaPorte M, Mann TH, Chen D, Hoffmann F, Ho J, Modliszewski J, Williams A, Liu Y, Wang Z, Liu J, Gao Y, Hu Z, Cho UH, Liu L, Wang Y, Hargreaves DC, Dotti G, Savoldo B, Thaxton JE, Milner JJ, Kaech SM, Wang W

Nature. 2026 Feb 4. doi: 10.1038/s41586-026-10100-x.
Niu J, Ma J, Zhu Y, Wang G, Xu X, Wang M, Wang Z, Bao X, Liu J, Ma E, Zhang X, Liu L, Zhang Y, Liu Q, Li C, Yin H, Xiang Y, Wang P, Cheng G

Science. 2026 Feb 5;391(6785):eadz4075. doi: 10.1126/science.adz4075. Epub 2026 Feb 5.
Lin Z, Li Y, Zhao Y, Liu D, Deng S, Gu J, Li Y, Zhao X, Wu P, Xiao Y, Su J, Sun Y, Zhang Y, Lee YL, Sato Y, Zeng H, Lu H, Zhang J, Ko JKY, Zhao J, Kawamura K, Ng EHY, Jiang S, Li Y, Xia X, Chan KKL, Yeung WSB, Wang TR, Liu K

Science. 2026 Feb 5;391(6785):eadv2600. doi: 10.1126/science.adv2600. Epub 2026 Feb 5.
Jiang X, Schaeffer L, Patni D, Russo T, Lee CZ, Aguilar C, Marques C, Jansen-West K, Hruska-Plochan M, Ray-Soni A, Lim SM, Held A, Yue M, Castellanos Otero P, Aryal S, Beaussant HDAM, Basu H, Takakuwa H, Daughrity LM, Ramesh N, Da Costa P, A A Quadros AR, Nolan M, Reyes CJF, Wheeler H, Moran LC, Griesman G, Wymann B, Trombetta BA, Lopez-De-Silanes ES, Canori M, Krishnan G, Vieira Souza Da Silva Y, Eriani G, Albers MW, Arnold SE, Song Y, Jain A, Chiu IM, Zhang YJ, Gao FB, Wainger BJ, Polymenidou M, Petrucelli L, Martin F, Lagier-Tourenne C

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE

Cell Metab. 2026 Feb 3;38(2):370-387.e10. doi: 10.1016/j.cmet.2025.12.017.
Ding N, Wu H, Hua Y, Hua R, Li B, Xie Y, Xiong Y, Bai T, Shi X, Shen T, Liu P, Liu J, Yang X, Xu Y, Meng Z, Lan B, Zhou J, Liu B, Shyy JY, Yuan Z, Wu Y, Li T

Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10076-0.
Li J, Tan JX, Chen ZJ, Zhang X, Bai XC

Nat Aging. 2026 Feb 3. doi: 10.1038/s43587-025-01054-2.
González-Gualda E, Reinius MAV, Macias D, Morsli S, Ge J, Olan I, Martín JE, Ou HL, Hartono M, Puerto-Camacho MP, Denholm M, Kieran R, Hoffmann R, Dane M, Veroutis D, Medrano G, Mulero F, Jimenez-Linan M, Fruk L, Martins CP, Barbacid M, Gorgoulis V, Korkola JE, Rassl DM, Doherty GJ, Rintoul RC, Narita M, Brenton JD, Muñoz-Espín D

Nat Metab. 2026 Feb 3. doi: 10.1038/s42255-026-01452-9.
Chen PX, Zhang L, Wu X, Liang Z, Hao X, Zhu Q, Liu Y, Zheng J, Zhang Q, Yang Q, Zhou F, Zhou C, Tian Y

Sci Transl Med. 2026 Feb 4;18(835):eadu6425. doi: 10.1126/scitranslmed.adu6425. Epub 2026 Feb 4.
Liu T, Zhou W, Fang C, Liang Y, Zhao Z, Cai A, Peng X, Ye X, Bai M, Hu X, Lin N, Zou X, Huang P

Cardiovasc Diabetol. 2026 Feb 4. doi: 10.1186/s12933-026-03084-5.
Han SS, Liu Q, Zeng ZM, Li Y, Li PW, Cheng FX, Zhong P, Li JB